Clinical Trial

TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma

Study acronym: TUNINTIL-2
Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is an open-label, phase 1 trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with lymphocyte-depleting chemotherapy and TILs in metastatic melanoma patients.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-05; most recent amendment 2026-03-04.
Status change: Recruiting → Active, Not Recruiting 2026-03-04
Trial Details
NCT Number NCT06961786
Lead Sponsor TILT Biotherapeutics Ltd.
Conditions Metastatic Melanoma
Enrollment 9 participants
Start Date 2025-06-25
Primary Completion 2026-11 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2026-03-05